Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

CDK4 activation/RB phosphorylation occurs in 50% of indolent but high-risk follicular lymphomas and implies susceptibility to dual CDK4 and BCL2 inhibition.

[1]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[2]  Konstantinos J. Mavrakis,et al.  The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma , 2011, Cell.

[3]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[4]  A. W. Harris,et al.  VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. , 2004, Blood.

[5]  M. Prados,et al.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.

[6]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[7]  Robert L. Sutherland,et al.  Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.

[8]  K. Basso,et al.  BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells , 2005, Nature Immunology.

[9]  G. Lozanski,et al.  A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. , 2004, Archives of Pathology & Laboratory Medicine.

[10]  L. Staudt,et al.  EZH2 mutations are frequent and represent an early event in follicular lymphoma. , 2013, Blood.

[11]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[12]  L. Staudt,et al.  Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. , 2014, Blood.

[13]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[14]  R. Gascoyne,et al.  Prognostic factors in follicular lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[16]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[17]  E. Campo,et al.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. , 1998, Blood.

[18]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[19]  M. Ewen,et al.  Bcl-2 Retards Cell Cycle Entry through p27Kip1, pRB Relative p130, and Altered E2F Regulation , 2000, Molecular and Cellular Biology.

[20]  L. Staudt.  A closer look at follicular lymphoma. , 2007, The New England journal of medicine.

[21]  W. Chan,et al.  A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. , 2003, Blood.

[22]  Ash A. Alizadeh,et al.  Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. , 2012, Blood.

[23]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[24]  A. Zelenetz,et al.  Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma , 2011, The Journal of experimental medicine.

[25]  A. Harwood,et al.  cAMP-induced degradation of cyclin D3 through association with GSK-3β , 2004, Journal of Cell Science.

[26]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[27]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[28]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[29]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[30]  W. Chan,et al.  Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. , 1995, Blood.

[31]  A. Strasser,et al.  The cell death inhibitor Bcl‐2 and its homologues influence control of cell cycle entry. , 1996, The EMBO journal.

[32]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[33]  P. Guldberg,et al.  Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma , 2000, Leukemia.

[34]  F. Sampson,et al.  Aggressive Non-Hodgkin’s Lymphoma , 2012, PharmacoEconomics.

[35]  C. Dunphy,et al.  Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. , 2007, Archives of pathology & laboratory medicine.

[36]  Steven K. Hanks,et al.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.

[37]  R. Gascoyne,et al.  Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. , 1998, Blood.

[38]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[39]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[40]  L. Díaz-Flores,et al.  Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma , 2001, Medical oncology.

[41]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[42]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[43]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[44]  J. M. Adams,et al.  Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. , 1996, Oncogene.

[45]  E. Campo,et al.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. , 1998, Blood.

[46]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.